Effects of different concentrations of anticoagulant on the in vitro characteristics of autologous whole blood.
BACKGROUND
Routinely, 450 mL of blood is collected into 63 mL of CPDA-1, for a final anticoagulant:blood ratio of approximately 1:7 in a whole-blood autologous unit. If less than 300 mL of blood is to be collected, the AABB standards suggest that there should be a proportionate decrease in anticoagulant. Data from an autologous blood program showed a range in volume from 92 mL to 667 mL per bag, which reflects an anticoagulant:blood ratio of 2:1 to 1:10.


METHODS
To determine the effects of these ratios on the in vitro function of RBCs at various anticoagulant ratios, blood was collected into different amounts of anticoagulant, and various measurements were made during storage.


RESULTS
The number of RBCs and the MCV remained constant over time, regardless of the anticoagulant dilution used. Plasma free Hb increased with time with all dilutions. At a 1:2 ratio, it rose from 734 mg per L on Day 1 to 1805 mg per L on Day 35, and at 1:8, it was 355 mg per L for Day 1 and 854 mg per L on Day 35. Plasma sodium decreased and the potassium increased over time with all dilutions. From Day 1 to Day 35, there was a nine-fold increase in potassium at both the 1:2 and 1:8 dilutions (2.4 to 22.9 mmol/L, 3.2 to 29.6 mmol/L, respectively). The LDH increased over time and the pH decreased in all of the dilutions. Osmotic fragility remained constant at the 1:8 dilution but decreased at all of the other dilutions with storage, with 44-percent fragility on Day 35 at the 1:2 ratio. The WBC and platelet counts decreased consistently over time. Overall, 1 percent of the autologous units were below the cutoff volume of 300 mL at which an adjustment of the anticoagulant volume is required.


CONCLUSIONS
Plasma Hb and plasma potassium concentrations are considerably higher in low-volume units, which indicates that deviation from standard collection procedures is deleterious to RBCs.
Cober
N
N
Division of Hematology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
Lacasse
M
M
Bart
B
B
Rock
G
G
D000225:Adenine / Q000494:pharmacology; D000925:Anticoagulants / Q000494:pharmacology*; D001772:Blood Cell Count; D001800:Blood Specimen Collection / Q000379:methods* / Q000592:standards; D001804:Blood Transfusion, Autologous; D002951:Citrates / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004909:Erythrocyte Indices / Q000187:drug effects; D004912:Erythrocytes / Q000187:drug effects; D005947:Glucose / Q000494:pharmacology; D006454:Hemoglobins / Q000032:analysis / Q000187:drug effects; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000032:analysis / Q000187:drug effects; D010710:Phosphates / Q000494:pharmacology; D011188:Potassium / Q000032:analysis; D012964:Sodium / Q000032:analysis; D013997:Time Factors
D000925:Anticoagulants; C034876:CPDA solutions; D002951:Citrates; D006454:Hemoglobins; D010710:Phosphates; D012964:Sodium; D007770:L-Lactate Dehydrogenase; D005947:Glucose; D000225:Adenine; D011188:Potassium